Targeting specific immune cells to reduce inflammation in atherosclerosis
Engineered Cytokines Targeting Lipid-Laden Macrophages
['FUNDING_OTHER'] · NORTHWESTERN UNIVERSITY · NIH-10723576
This study is testing a new treatment for atherosclerosis that uses specially designed proteins to help calm down the inflammation caused by certain immune cells in your body, aiming to improve heart health for people dealing with this condition.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10723576 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treat atherosclerosis by engineering cytokines that specifically target lipid-laden macrophages, which are key players in the inflammatory process of this disease. The study utilizes a unique protein fusion that combines an antibody fragment that binds to low-density lipoprotein (LDL) with an anti-inflammatory cytokine, IL-10. By delivering this engineered cytokine directly to inflamed macrophages, the goal is to reduce inflammation and improve outcomes for patients with atherosclerosis. The research will explore how these engineered cytokines work at the molecular level to suppress inflammation in affected tissues.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atherosclerosis or those exhibiting high levels of inflammation related to lipid metabolism.
Not a fit: Patients who do not have atherosclerosis or related inflammatory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for atherosclerosis, potentially reducing cardiovascular events and improving patient quality of life.
How similar studies have performed: Previous research has shown promise in targeting macrophages for immunomodulation, suggesting that this approach could be a significant advancement in treating inflammatory diseases.
Where this research is happening
Chicago, UNITED STATES
- NORTHWESTERN UNIVERSITY — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VOLPATTI, LISA R — NORTHWESTERN UNIVERSITY
- Study coordinator: VOLPATTI, LISA R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.